Lawrence A. Leiter


Associate Scientist, Li Ka Shing Knowledge Institute


Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.


Recent Publications

  1. Cahn, A, Wiviott, SD, Mosenzon, O, Murphy, SA, Goodrich, EL, Yanuv, I et al.. Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents -Post-hoc Analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.14179. PubMed PMID:32844557 .
  2. Garg, V, Verma, S, Connelly, KA, Yan, AT, Sikand, A, Garg, A et al.. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabol Open. 2020;7 :100039. doi: 10.1016/j.metop.2020.100039. PubMed PMID:32812924 PubMed Central PMC7424781.
  3. Bonaca, MP, Wiviott, SD, Zelniker, TA, Mosenzon, O, Bhatt, DL, Leiter, LA et al.. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142 (8):734-747. doi: 10.1161/CIRCULATIONAHA.119.044775. PubMed PMID:32795086 .
  4. Verma, S, McGuire, DK, Bain, SC, Bhatt, DL, Leiter, LA, Mazer, CD et al.. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.14160. PubMed PMID:32744418 .
  5. Arnold, SV, Gosch, K, Wong, ND, Hejjaji, V, Goyal, A, Leiter, LA et al.. Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes. Endocrinol Diabetes Metab. 2020;3 (3):e00126. doi: 10.1002/edm2.126. PubMed PMID:32704552 PubMed Central PMC7375067.
  6. Semnani-Azad, Z, Khan, TA, Blanco Mejia, S, de Souza, RJ, Leiter, LA, Kendall, CWC et al.. Association of Major Food Sources of Fructose-Containing Sugars With Incident Metabolic Syndrome: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3 (7):e209993. doi: 10.1001/jamanetworkopen.2020.9993. PubMed PMID:32644139 PubMed Central PMC7348689.
  7. Banach, M, Duell, PB, Gotto, AM Jr, Laufs, U, Leiter, LA, Mancini, GBJ et al.. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020; :. doi: 10.1001/jamacardio.2020.2314. PubMed PMID:32609313 PubMed Central PMC7330832.
  8. Cukierman-Yaffe, T, Gerstein, HC, Colhoun, HM, Diaz, R, García-Pérez, LE, Lakshmanan, M et al.. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19 (7):582-590. doi: 10.1016/S1474-4422(20)30173-3. PubMed PMID:32562683 .
  9. Rabi, DM, McBrien, KA, Sapir-Pichhadze, R, Nakhla, M, Ahmed, SB, Dumanski, SM et al.. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36 (5):596-624. doi: 10.1016/j.cjca.2020.02.086. PubMed PMID:32389335 .
  10. Leiter, LA, Bain, SC, Bhatt, DL, Buse, JB, Mazer, CD, Pratley, RE et al.. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22 (9):1690-1695. doi: 10.1111/dom.14079. PubMed PMID:32372454 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto